Integral Health Asset Management, LLC Chemo Centryx, Inc. Transaction History

Integral Health Asset Management, LLC

$850 Million
Q3 2024

Shares

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 03, 2022	BUY	$15.36 - $27.51 $2.67 Million - $4.79 Million	174,029 Added 43.51%	574,029 $14.2 Million
Q1 2022 May 12, 2022	BUY	$22.22 - $39.12 $4.44 Million - $7.82 Million	200,000 Added 100.0%	400,000 $10 Million
Q4 2021 Feb 02, 2022	SELL	$18.38 - $40.5 $1.84 Million - $4.05 Million	-100,000 Reduced 33.33%	200,000 $7.28 Million
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $1.65 Million - $2.48 Million	125,000 Added 71.43%	300,000 $5.13 Million
Q2 2021 Aug 30, 2021	SELL	$9.59 - $50.88 $1.68 Million - $8.9 Million	-175,000 Reduced 50.0%	175,000 $2.34 Million
Q2 2021 Aug 13, 2021	BUY	$9.59 - $50.88 $1.87 Million - $9.92 Million	195,000 Added 125.81%	350,000 $4.69 Million
Q1 2021 May 10, 2021	SELL	$49.53 - $68.4 $1.24 Million - $1.71 Million	-25,000 Reduced 13.89%	155,000 $7.94 Million
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $236,250 - $325,800	-5,000 Reduced 2.7%	180,000 $11.1 Million
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $1.62 Million - $2.16 Million	35,000 Added 23.33%	185,000 $10.1 Million
Q2 2020 Aug 14, 2020	SELL	$38.58 - $65.07 $1.54 Million - $2.6 Million	-40,000 Reduced 21.05%	150,000 $8.63 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $4.58 Million - $7.11 Million	140,000 Added 280.0%	190,000 $7.63 Million
Q4 2019 Feb 13, 2020	BUY	$6.81 - $39.55 $340,500 - $1.98 Million	50,000 New	50,000 $1.98 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Integral Health Asset Management, LLC with notifications on news.